Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
Adult
Age Factors
Benzamides
/ therapeutic use
Child
Consensus
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Indazoles
/ therapeutic use
Membrane Glycoproteins
/ genetics
Molecular Targeted Therapy
Neoplasms
/ diagnosis
Oncogene Proteins, Fusion
/ analysis
Protein Kinase Inhibitors
/ therapeutic use
Pyrazoles
/ therapeutic use
Pyrimidines
/ therapeutic use
Receptor, trkA
/ genetics
Receptor, trkB
/ genetics
Receptor, trkC
/ genetics
Reverse Transcriptase Polymerase Chain Reaction
Societies, Medical
Spain
Gene fusions
Molecular oncology
Mutations
Neoplasm
Target therapies
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
30
11
2020
accepted:
24
01
2021
pubmed:
24
2
2021
medline:
1
12
2021
entrez:
23
2
2021
Statut:
ppublish
Résumé
The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management of patients presenting with tumours with these alterations. Tumours that harbour NTRK fusions are found in both adults and children; and they are either rare tumours with common NTRK fusions that may be diagnostic, or more prevalent tumours with rare NTRK fusions. To assess currently available evidence on this matter, three key Spanish medical societies (the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Pathological Anatomy (SEAP), and the Spanish Society of Paediatric Haematology and Oncology (SEHOP) have brought together a group of experts to develop a consensus document that includes guidelines on the diagnostic, clinical, and therapeutic aspects of NTRK-fusion tumours. This document also discusses the challenges related to the routine detection of these genetic alterations in a mostly public Health Care System.
Identifiants
pubmed: 33620682
doi: 10.1007/s12094-021-02558-0
pii: 10.1007/s12094-021-02558-0
pmc: PMC8238709
doi:
Substances chimiques
Benzamides
0
Indazoles
0
Membrane Glycoproteins
0
NTRK1 protein, human
0
NTRK3 protein, human
0
Oncogene Proteins, Fusion
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
Receptor, trkA
EC 2.7.10.1
Receptor, trkB
EC 2.7.10.1
Receptor, trkC
EC 2.7.10.1
tropomyosin-related kinase-B, human
EC 2.7.10.1
entrectinib
L5ORF0AN1I
larotrectinib
PF9462I9HX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1529-1541Références
Mol Cell Biol. 1994 Jan;14(1):759-67
pubmed: 8264643
J Mol Diagn. 2014 Jul;16(4):405-17
pubmed: 24813172
Future Oncol. 2005 Oct;1(5):689-98
pubmed: 16556046
Ann Oncol. 2016 Sep;27 Suppl 3:iii16-iii24
pubmed: 27573752
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Annu Rev Biochem. 2003;72:609-42
pubmed: 12676795
J Thorac Oncol. 2019 Dec;14(12):2120-2132
pubmed: 31349061
Arch Pathol Lab Med. 2014 Nov;138(11):1520-30
pubmed: 25357115
Am J Surg Pathol. 2000 Jul;24(7):937-46
pubmed: 10895816
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Hum Pathol. 2013 Oct;44(10):1982-8
pubmed: 23773480
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Nat Med. 2019 Sep;25(9):1422-1427
pubmed: 31406350
J Mol Diagn. 2019 Jul;21(4):553-571
pubmed: 31075511
Genes Chromosomes Cancer. 2020 Mar;59(3):178-188
pubmed: 31652375
Nat Med. 2013 Nov;19(11):1469-1472
pubmed: 24162815
Mod Pathol. 2019 Jan;32(1):147-153
pubmed: 30171197
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
J Clin Pathol. 2019 Jul;72(7):460-467
pubmed: 31072837
Cancer Res. 2019 Jul 1;79(13):3163-3168
pubmed: 31196931
J Clin Oncol. 2019 Feb 20;37(6):513-524
pubmed: 30592640
J Mol Diagn. 2017 May;19(3):341-365
pubmed: 28341590
Sci Rep. 2017 Feb 09;7:42259
pubmed: 28181564
Cancer Discov. 2016 Jan;6(1):14-6
pubmed: 26747892
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Nat Genet. 2013 Oct;45(10):1141-9
pubmed: 23917401
Cancer. 2018 Nov 1;124(21):4241-4247
pubmed: 30204247
Mod Pathol. 2000 Jan;13(1):29-36
pubmed: 10658907
Cancer Discov. 2018 Oct;8(10):1227-1236
pubmed: 30093503
Arch Pathol Lab Med. 2021 Aug 1;145(8):1031-1040
pubmed: 33112951
J Transl Med. 2016 Dec 14;14(1):339
pubmed: 27974047
Pathol Int. 2019 Feb;69(2):94-96
pubmed: 30707464
Am J Surg Pathol. 2017 Nov;41(11):1547-1551
pubmed: 28719467
Cancer Cell. 2002 Nov;2(5):367-76
pubmed: 12450792
Clin Transl Oncol. 2013 Jul;15(7):503-8
pubmed: 23359174
Oncologist. 2014 Mar;19(3):235-42
pubmed: 24563076
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Ann Oncol. 2020 Sep;31(9):1207-1215
pubmed: 32422171
Mol Cell Endocrinol. 2010 May 28;321(1):44-9
pubmed: 19883730
JCO Precis Oncol. 2018;2018:
pubmed: 30637364
Arch Pathol Lab Med. 2016 Jan;140(1):29-40
pubmed: 25965939
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22
pubmed: 31738428
Mod Pathol. 2020 May;33(5):924-932
pubmed: 31792356
Am J Surg Pathol. 2015 Nov;39(11):1458-67
pubmed: 26291510
ESMO Open. 2016 Mar 18;1(2):e000023
pubmed: 27843590
Clin Transl Oncol. 2020 Jul;22(7):989-1003
pubmed: 31598903
Mod Pathol. 2017 Aug;30(8):1086-1099
pubmed: 28548128
Cancer Discov. 2015 Jan;5(1):25-34
pubmed: 25527197
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Am J Pathol. 1998 Nov;153(5):1451-8
pubmed: 9811336
Expert Rev Clin Pharmacol. 2019 Nov;12(11):1033-1036
pubmed: 31633383
Am J Surg Pathol. 2016 Jan;40(1):3-13
pubmed: 26492182
Cancer Discov. 2017 Sep;7(9):963-972
pubmed: 28578312
J Pathol. 2016 Apr;238(5):700-10
pubmed: 26863915
Genomics. 1995 Mar 20;26(2):390-3
pubmed: 7601468
Mod Pathol. 2020 Jan;33(1):38-46
pubmed: 31375766
PLoS One. 2011 Feb 17;6(2):e16871
pubmed: 21379385
Oncogene. 2015 Sep 10;34(37):4845-54
pubmed: 25500544
Clin Cancer Res. 2011 May 1;17(9):2638-45
pubmed: 21242122